Abstract:Taxol (paclitaxel) response is profiled against a panel of clinical missence mutations in β‐tubulin at molecular and cellular levels, aiming to understanding of molecular mechanism and biological implication underlying drug resistance and sensitivity conferring from tubulin mutations. The Paclitaxel‐resistant mutations can be classified into three types, namely nonbonded interaction broken due to mutation, steric hindrance caused by mutation, and conformational change upon mutation. Taxol (paclitaxel) is the first approved microtubule‐stabilizing agent (MSA) by binding stoichiometrically to tubulin, which is considered to be one of the most significant advances in first‐line chemotherapy against diverse tumors. However, a large number of residue missence mutations harboring in the tubulin have been observed to cause acquired drug resistance, largely limiting the clinical application of Taxol and its analogs in chemotherapy. A systematic investigation of the intermolecular interactions between the Taxol and various tubulin mutants would help to establish a comprehensive picture of drug response to tubulin mutations in clinical treatment of cancer, and to design new MSA agents with high potency and selectivity to overcome drug resistance. In this study, we described an integration of in silico analysis and in vitro assay (iSiV) to profile Taxol against a panel of 149 clinically observed, cancer‐associated missence mutations in β‐tubulin at molecular and cellular levels, aiming to a systematic understanding of molecular mechanism and biological implication underlying drug resistance and sensitivity conferring from tubulin mutations. It is revealed that the Taxol‐resistant mutations can be classified into three types: (I) nonbonded interaction broken due to mutation, (II) steric hindrance caused by mutation, and (III) conformational change upon mutation. In addition, we identified three new Taxol‐resistant mutations (C239Y, T274I, and R320P) that can largely reduce the binding affinity of Taxol to tubulin at molecular level, in which the T274I and R320P were observed to considerably impair the antitumor activity of Taxol at cellular level. Moreover, a novel drug‐susceptible mutation (M363T) was also identified, which improves Taxol affinity by 2.6‐fold and decreases Taxol antitumor EC50 values from 29.4 to 18.7 μM.

Design of a Molecular Dynamics Model for High-Performance Computing of Conformational Changes in Microtubule Protofilaments Associated with the Anticancer Drug Taxol

Analysis of a microscopic stochastic model of microtubule dynamic instability

Modeling the effects of drug binding on the dynamic instability of microtubules

Data-Driven Equation-Free Dynamics Applied to Many-Protein Complexes: The Microtubule Tip Relaxation

Modulation of taxane binding to tubulin curved and straight conformations by systematic 3′N modification provides for improved microtubule binding, persistent cytotoxicity and in vivo potency

Chemomechanical simulation of microtubule dynamics with explicit lateral bond dynamics

Bridging-scale modeling of biomechanical behavior of microtubules

A floor-field model of tau-taxol competition explains tau envelope dynamics on taxol-stabilized microtubules

Systematic profiling of Taxol resistance and sensitivity to tubulin missence mutations at molecular and cellular levels

Dynamic information of the time-dependent tobullian biomolecular structure using a high-accuracy size-dependent theory

Tubulin bond energies and microtubule biomechanics determined from nanoindentation in silico

Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents

Computational Approaches to the Rational Design of Tubulin-Targeting Agents

Unravelling the covalent binding of zampanolide and taccalonolide AJ to a minimalist representation of a human microtubule

Discovery of microtubule stabilizers with novel scaffold structures based on virtual screening, biological evaluation, and molecular dynamics simulation

Drug Delivery Process Simulation - Quantifying the Conformation Dynamics of Paclitaxel and Cremophor EL

Dynamic instabilities in the kinetics of growth and disassembly of microtubules

Discovery of Novel Tubulin Polymerization Inhibitors by Utilizing 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation

Differential Effects of Natural Product Microtubule Stabilizers on Microtubule Assembly: Single Agent and Combination Studies with Taxol, Epothilone B, and Discodermolide

Exploration of anti-tumour inhibitors from colchicine derivatives based on 3D-QSAR, molecular docking and molecular dynamics simulations

A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells